Date	:2023/3/1	.5				
	Name: Houle					
Man from	Manuscript Title: Harmine loaded Au@MSNs@PEG@Asp6 nano-composites for treatment of spinal metastasis rom lung adenocarcinoma by targeting ANXA9 Hanuscript number (if known):					
relat parti to tra	ed to the content of your n es whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment lf you are in doubt about whether to list a so.			
	following questions apply tuscript only.	o the author's relationshi	ps/activities/interests as they relate to the <u>current</u>			
to th medi In ite	e epidemiology of hyperterication, even if that medica	nsion, you should declare ation is not mentioned in to port for the work reporte	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.  d in this manuscript without time limit. For all other items,			
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)			
		Time frame: Since the initi	al planning of the work			
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone				
2	Crants or contracts from	Time frame: pas	t 36 months			
	Grants or contracts from any entity (if not indicated	XNone				

in item #1 above).

Royalties or licenses

Consulting fees

4

X\_\_None

\_X\_\_None

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
8	pending	XNOTIE	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

None		

Please place an "X" next to the following statement to indicate your agreement:

Data	2022/2/45
	2023/3/15
Your Name:	Fancheng Chen
Manuscript Title:	Harmine loaded Au@MSNs@PEG@Asp6 nano-composites for treatment of spinal metastasis
from lung adenocar	cinoma by targeting ANXA9
Manuscript number	(if known):
·	
In the interest of tra	ansparency, we ask you to disclose all relationships/activities/interests listed below that are
	ent of your manuscript. "Related" means any relation with for-profit or not-for-profit third ests may be affected by the content of the manuscript. Disclosure represents a commitment

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a

relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
			plaining of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)  No time limit for this item.		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

form.

		1	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
	_		
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		
ы.		COLUMN CO	· Harantana Karantana

None		

Please place an "X" next to the following statement to indicate your agreement:

Date:	2023/3/15				
Your Name:	our Name: Annan Hu				
Manuscript Title:	Harmine loaded Au@MSNs@PEG@	Asp6 nano-composites for treatment of spinal metastasis			
from lung adenocar	cinoma by targeting ANXA9				
Manuscript number	r (if known):				
related to the conte parties whose inter to transparency and	ent of your manuscript. "Related" mea ests may be affected by the content of	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.			
The following quest manuscript only.	ions apply to the author's relationship	os/activities/interests as they relate to the <u>current</u>			
to the epidemiolog	• • •	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.			
	eport all support for the work reported disclosure is the past 36 months.	I in this manuscript without time limit. For all other items			
	Name all entities with	Specifications/Comments			
	whom you have this	(e.g., if payments were made to you or to your			
	relationship or indicate	institution)			
	none (add rows as				
	needed) Time frame: Since the initia				

		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

		1	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
	_		
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		
ы.		COLUMN CO	· Harantana Karantana

None		

Please place an "X" next to the following statement to indicate your agreement:

Date	e:2023/3/1	5			
Your	r Name: Haifer	ng Liang			
Man	Nanuscript Title: Harmine loaded Au@MSNs@PEG@Asp6 nano-composites for treatment of spinal metastasis				
from	n lung adenocarcinoma by ta	argeting ANXA9			
Man	uscript number (if known):				
In th	e interest of transparency,	we ask you to disclose all	relationships/activities/interests listed below that are		
			ns any relation with for-profit or not-for-profit third		
•	-	-	the manuscript. Disclosure represents a commitment		
	•	•	If you are in doubt about whether to list a		
relat	tionship/activity/interest, it	is preferable that you do	so.		
The	following questions apply to	o the author's relationship	os/activities/interests as they relate to the <u>current</u>		
<u>man</u>	uscript only.				
The	authar/a ralationahina/activ	itios/interests should be a	lating d byggdly. The group of the result management maybeing		
	•	_	lefined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive		
	ication, even if that medica	· ·	· · · · · · · · · · · · · · · · · · ·		
	industry death in that incured		ic manager pu		
In ite	em #1 below, report all sup	port for the work reported	l in this manuscript without time limit. For all other items,		
	time frame for disclosure is	•	,		
		·			
		Name all entities with	Specifications/Comments		
		whom you have this	(e.g., if payments were made to you or to your		
		relationship or indicate	institution)		
		none (add rows as	,		
		needed)			
		Time frame: Since the initia	l planning of the work		
1	All support for the present	XNone			
	manuscript (e.g., funding,				
	provision of study materials, medical writing, article				
	processing charges, etc.)				
	No time limit for this item.				
			<del> </del>		
			+		
		Time frame: past	26 months		

Grants or contracts from

in item #1 above).

Consulting fees

Royalties or licenses

3

4

any entity (if not indicated

X\_\_None

\_X\_\_None

X\_\_None

		1	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
	_		
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		
ы.		COLUMN CO	· Harantana Karantana

None		

Please place an "X" next to the following statement to indicate your agreement:

Date:	2023/3/15
Your Name:	Yun Liang
	Harmine loaded Au@MSNs@PEG@Asp6 nano-composites for treatment of spinal metastasis
from lung adenoca	rcinoma by targeting ANXA9
Manuscript numbe	r (if known):
related to the cont parties whose inter to transparency an	cansparency, we ask you to disclose all relationships/activities/interests listed below that are ent of your manuscript. "Related" means any relation with for-profit or not-for-profit third rests may be affected by the content of the manuscript. Disclosure represents a commitment d does not necessarily indicate a bias. If you are in doubt about whether to list a ty/interest, it is preferable that you do so.
The following ques manuscript only.	tions apply to the author's relationships/activities/interests as they relate to the <u>current</u>
to the epidemiolog	onships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains by of hypertension, you should declare all relationships with manufacturers of antihypertensive that medication is not mentioned in the manuscript.
	eport all support for the work reported in this manuscript without time limit. For all other items

ıs,

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
			plaining of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)  No time limit for this item.		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

		1	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
	_		
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		
ы.		COLUMN CO	· Harantana Karantana

None		

Please place an "X" next to the following statement to indicate your agreement:

Date	: 2023/3/	15		
Your	Name:Naga	shree Seetharamu		
Manuscript Title: Harmine loaded Au@MSNs@PEG@Asp6 nano-composites for treatment of s metastasis from lung adenocarcinoma by targeting ANXA9 Manuscript number (if known):				
relat parti to tra	ed to the content of your i es whose interests may be	manuscript. "Related" me e affected by the content on necessarily indicate a bias.	I relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a poso.	
	following questions apply uscript only.	to the author's relationsh	ips/activities/interests as they relate to the <u>current</u>	
to th		ension, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.	
	em #1 below, report all sup ime frame for disclosure is	•	ed in this manuscript without time limit. For all other items,	
		Name all entities with	Specifications/Comments	
		whom you have this	log if nayments were made to you or to your	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

		1	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
	_		
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		
ы.		COLUMN CO	· Harantana Karantana

Please place an "X" next to the following statement to indicate your agreement:

Date	e:20	23/3/15			
You	our Name: Huiren Wang				
Mar	Manuscript Title: Harmine loaded Au@MSNs@PEG@Asp6 nano-composites for treatment of spinal metastasi				
	_	ma by targeting ANXA9			
Mar	nuscript number (if k	nown):			
rela part to tr	ted to the content of ies whose interests r ransparency and doe	your manuscript. "Related" mea may be affected by the content o	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.		
	following questions nuscript only.	apply to the author's relationship	os/activities/interests as they relate to the current		
to th	ne epidemiology of h		defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.		
	· · · · · · · · · · · · · · · · · · ·	all support for the work reported sure is the past 36 months.	I in this manuscript without time limit. For all other items		
		Name all entities with	Specifications/Comments		
		whom you have this	(e.g., if payments were made to you or to your		
		relationship or indicate	institution)		
		none (add rows as			
		needed)			
1	All support for the pre	Time frame: Since the initia	ir planning of the work		

		relationship or indicate none (add rows as needed)	institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

		1	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
	-		
7	Support for attending meetings and/or travel	XNone	
	-		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
42	services	V None	
13	Other financial or non-	XNone	
	financial interests		
		. (1)	Cities Const.

Please place an "X" next to the following statement to indicate your agreement:

Date:	2023/3/15	
Your Name:	Jian Dong	
Manuscript Title:	Harmine loaded	d Au@MSNs@PEG@Asp6 nano-composites for treatment of spinal metastasis
from lung adeno	arcinoma by targetir	ng ANXA9
Manuscript numb	er (if known):	
related to the cor parties whose int to transparency a	ntent of your manusc erests may be affect nd does not necessa	k you to disclose all relationships/activities/interests listed below that are cript. "Related" means any relation with for-profit or not-for-profit third ed by the content of the manuscript. Disclosure represents a commitment rily indicate a bias. If you are in doubt about whether to list a ferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
1	All accordant for the process	planning of the work			
1	All support for the present manuscript (e.g., funding,	XNone			
	provision of study materials,				
	medical writing, article				
	processing charges, etc.)				
	No time limit for this item.				
	Time frame: past 36 months				
2	Grants or contracts from	XNone			
	any entity (if not indicated				
_	in item #1 above).				
3	Royalties or licenses	XNone			
4	Consulting fees	X None			
'	Consuming rees				

		1	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
	-		
7	Support for attending meetings and/or travel	XNone	
	-		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
42	services	V None	
13	Other financial or non-	XNone	
	financial interests		
		. (1)	Cities Const.

None			

Please place an "X" next to the following statement to indicate your agreement: